JP2005535636A - インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 - Google Patents

インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 Download PDF

Info

Publication number
JP2005535636A
JP2005535636A JP2004517494A JP2004517494A JP2005535636A JP 2005535636 A JP2005535636 A JP 2005535636A JP 2004517494 A JP2004517494 A JP 2004517494A JP 2004517494 A JP2004517494 A JP 2004517494A JP 2005535636 A JP2005535636 A JP 2005535636A
Authority
JP
Japan
Prior art keywords
interferon
administered
treatment
tac
interferon beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004517494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535636A5 (enExample
Inventor
ローランド マーティン
ヘンリー エフ． マクファーランド
ビビアンナ ビエルコバ
トマス ウォルドマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005535636(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2005535636A publication Critical patent/JP2005535636A/ja
Publication of JP2005535636A5 publication Critical patent/JP2005535636A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
JP2004517494A 2002-06-28 2002-11-27 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 Withdrawn JP2005535636A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39302102P 2002-06-28 2002-06-28
PCT/US2002/038290 WO2004002500A1 (en) 2002-06-28 2002-11-27 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011082497A Division JP2011157378A (ja) 2002-06-28 2011-04-04 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法

Publications (2)

Publication Number Publication Date
JP2005535636A true JP2005535636A (ja) 2005-11-24
JP2005535636A5 JP2005535636A5 (enExample) 2006-01-19

Family

ID=30000962

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2004517494A Withdrawn JP2005535636A (ja) 2002-06-28 2002-11-27 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
JP2004518039A Withdrawn JP2006508039A (ja) 2002-06-28 2003-06-27 多発性硬化症を治療する方法
JP2009284862A Withdrawn JP2010132660A (ja) 2002-06-28 2009-12-16 多発性硬化症を治療する方法
JP2011082497A Withdrawn JP2011157378A (ja) 2002-06-28 2011-04-04 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
JP2012217520A Withdrawn JP2013032372A (ja) 2002-06-28 2012-09-28 多発性硬化症を治療する方法
JP2013086246A Pending JP2013139478A (ja) 2002-06-28 2013-04-17 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
JP2014147314A Expired - Lifetime JP5905534B2 (ja) 2002-06-28 2014-07-18 多発性硬化症を治療する方法
JP2016030540A Withdrawn JP2016145220A (ja) 2002-06-28 2016-02-22 多発性硬化症を治療する方法

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2004518039A Withdrawn JP2006508039A (ja) 2002-06-28 2003-06-27 多発性硬化症を治療する方法
JP2009284862A Withdrawn JP2010132660A (ja) 2002-06-28 2009-12-16 多発性硬化症を治療する方法
JP2011082497A Withdrawn JP2011157378A (ja) 2002-06-28 2011-04-04 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
JP2012217520A Withdrawn JP2013032372A (ja) 2002-06-28 2012-09-28 多発性硬化症を治療する方法
JP2013086246A Pending JP2013139478A (ja) 2002-06-28 2013-04-17 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
JP2014147314A Expired - Lifetime JP5905534B2 (ja) 2002-06-28 2014-07-18 多発性硬化症を治療する方法
JP2016030540A Withdrawn JP2016145220A (ja) 2002-06-28 2016-02-22 多発性硬化症を治療する方法

Country Status (15)

Country Link
US (11) US7575742B2 (enExample)
EP (3) EP3269377A1 (enExample)
JP (8) JP2005535636A (enExample)
AU (3) AU2002368055B2 (enExample)
CA (3) CA2490804C (enExample)
CY (2) CY2016043I1 (enExample)
DK (2) DK2314627T3 (enExample)
ES (2) ES2637011T3 (enExample)
HK (1) HK1249850A1 (enExample)
HU (2) HUE036677T2 (enExample)
IL (2) IL165973A (enExample)
LU (1) LU93315I2 (enExample)
PT (2) PT2314627T (enExample)
SI (2) SI2314627T1 (enExample)
WO (2) WO2004002500A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2676065C (en) * 2001-04-26 2011-02-01 Motion Technologies, Llc Continuously variable transmission
CA2490804C (en) * 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
US20060134750A1 (en) * 2004-03-10 2006-06-22 Pepgen Corporation Method of treatment using interferon-tau
EP1845925B1 (en) 2005-01-12 2016-08-24 Biogen MA Inc. Method for delivering interferon-beta
US20080279819A1 (en) * 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
BRPI0918842A2 (pt) * 2008-08-28 2015-12-08 Abbott Biotherapeutics Corp método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r
EP2355660A4 (en) * 2008-10-13 2012-05-02 Biovista Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
WO2010068923A2 (en) * 2008-12-12 2010-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents that selectively inhibit cd25 on dendritic cells or t cells and their use
AU2010286427A1 (en) * 2009-08-31 2012-03-08 Abbott Biotherapeutics Corp. Use of an immunoregulatory NK cell population for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
EP2741773A1 (en) 2011-08-08 2014-06-18 AbbVie Biotherapeutics Inc. Methods of treating progressive forms of multiple sclerosis
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
EP3978512A1 (en) 2015-10-09 2022-04-06 Bioniz, LLC Modulating gamma-c-cytokine activity
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
DE102017104088A1 (de) * 2017-02-28 2018-08-30 L&O Hunting Group GmbH Integralschalldämpfer für einen Gewehrlauf
KR102707650B1 (ko) 2017-04-07 2024-09-19 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 안정한 조절자
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
WO2021026362A1 (en) * 2019-08-07 2021-02-11 Edifice Health, Inc. Treatment of prevention of cardiovascular disease
US20240043499A1 (en) 2022-08-07 2024-02-08 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4819150A (en) 1985-04-05 1989-04-04 Unisys Corporation Array for simulating computer functions for large computer systems
US5336489A (en) 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5011684A (en) 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5695927A (en) 1988-03-31 1997-12-09 The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology Monoclonal antibodies specific for HIV and the hybridomas for production thereof
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
US5152980A (en) 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
US5620686A (en) 1990-09-28 1997-04-15 British Technology Group Limited Antigen-antibody conjugates
US5747444A (en) * 1990-10-09 1998-05-05 Chiron Corporation Method of treating graft-versus-host disease
FR2672291A1 (fr) 1991-01-31 1992-08-07 Inst Nat Sante Rech Med Composition d'anticorps diriges contre le recepteur de l'interleukine-2 humaine ou animale.
GB9115010D0 (en) 1991-07-11 1991-08-28 Wellcome Found Antibody
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5571507A (en) 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
DK0699077T3 (da) 1993-05-07 2002-01-21 Bio Merieux Inc Immunogele HIV-komplekser
WO1995005734A1 (en) 1993-08-27 1995-03-02 The Pillsbury Company Mechanical gas flushing system
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
AU3710597A (en) * 1997-08-06 1999-03-01 Laboratorio Medinfar-Produtos Farmaceuticos, Lda Dna integration into "mycobacterium spp." genome by trans-complementation using a site-specific integration system
WO2000025816A1 (en) 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
WO2001080891A1 (en) * 2000-04-25 2001-11-01 Nippon Organon K. K. Remedies for interstitial pneumonia, method of constructing animal model of this disease and screening method with the use of the same
WO2002081508A2 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
CA2490804C (en) * 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
WO2004003156A2 (en) 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN5005001832, Ｐａｔｙ，Ｄ．Ｗ． ｅｔ ａｌ．, "Ｉｎｔｅｒｆｅｒｏｎ ｂｅｔａ−１ｂ ｉｓ ｅｆｆｅｃｔｉｖｅ ｉｎ ｒｅｌａｐｓｉｎｇ−ｒｅｍｉｔｔｉｎｇ ｍｕｌｔｉｐｌｅ ｓｃｌｅｒｏｓｉｓ", Ｎｅｕｒｏｌｏｇｙ, 199304, Ｖｏｌ．４３，Ｎｏ．４, Ｐ．６６２−６６７ *
JPN6010056736, 村井弘之 他１名, "綜説 『多発性硬化症：研究と治療の進歩と展望』", 日本臨床, 200106, 第５９巻， 第６号, Ｐ．１２１１−１２１８, JP *
JPN6010056739, 糸山泰人, "平成８年度日本内科学会生涯教育講演会 Ａセッション 『ＩＩ．神経 １．多発性硬化症の病態と治療』", 日本内科学会雑誌, 19970310, 第８６巻，第３号, Ｐ．４１６−４１９, JP *
JPN6010056741, 糸山泰人, "疾患概念の変遷−神経研究のあゆみ 連載 ９ 『多発性硬化症 −発症機転と新しい治療法』", 医学のあゆみ, 19970726, Ｖｏｌ．１８２，Ｎｏ．４, Ｐ．２３５−２３８, JP *
JPN6010056743, 小澤恭子, "特集／シンポジウム：免疫性神経疾患の治療 『多発性硬化症のインターフェロン療法』", 神経治療学, 199811, Ｖｏｌ．１５，Ｎｏ．６, Ｐ．５９５−５９７, JP *
JPN6010056747, Ｗｅｋｅｒｌｅ，Ｈ． ｅｔ ａｌ．, "Ｓｕｐｐｒｅｓｓｉｏｎ ｏｆ Ｔ−ｃｅｌｌ ｍｅｄｉａｔｅｄ ａｕｔｏｉｍｍｕｎｅ ｄｉｓｅａｓｅ ｗｉｔｈ ａｎｔｉｂｏｄｉｅｓ ａｇａｉｎｓｔ ｔｈｅ ｉｎｔｅｒｌｅｕｋｉｎ−２ ｒｅｃｅｐｔｏｒ", Ａｎｎ． Ｎ．Ｙ． Ａｃａｄ． Ｓｃｉ．, 198607, Ｖｏｌ．４７５, Ｐ．４０１−４０３ *
JPN6010056750, Ｑｕｅｅｎ，Ｃ． ｅｔ ａｌ．, "Ａ ｈｕｍａｎｉｚｅｄ ａｎｔｉｂｏｄｙ ｔｈａｔ ｂｉｎｄｓ ｔｏ ｔｈｅ ｉｎｔｅｒｌｅｕｋｉｎ ２ ｒｅｃｅｐｔｏｒ", Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ． ＵＳＡ, 19891215, Ｖｏｌ．８６，Ｎｏ．２４, Ｐ．１００２９−１００３３ *
JPN6010056754, Ｋｒｕｅｇｅｒ，Ｊ．Ｇ． ｅｔ ａｌ．, "Ｓｕｃｃｅｓｓｆｕｌ ｉｎ ｖｉｖｏ ｂｌｏｃｋａｄｅ ｏｆ ＣＤ２５ （ｈｉｇｈ−ａｆｆｉｎｉｔｙ ｉｎｔｅｒｌｅｕｋｉｎ ２ ｒｅｃｅｐｔｏｒ） ｏｎ Ｔ ｃｅｌｌｓ ｂｙ ａｄｍｉｎｉｓｔｒａｔ", Ｊ． Ａｍ． Ａｃａｄ． Ｄｅｒｍａｔｏｌ．, 200009, Ｖｏｌ．４３，Ｎｏ．３, Ｐ．４４８−４５８ *

Also Published As

Publication number Publication date
US8298525B2 (en) 2012-10-30
CA2490804C (en) 2016-12-06
CY2016043I2 (el) 2017-04-05
EP1539200B1 (en) 2014-05-28
EP2314627A3 (en) 2011-05-11
DK1539200T3 (da) 2014-06-30
IL165973A (en) 2015-10-29
SI2314627T1 (sl) 2017-10-30
CA2490186C (en) 2014-04-15
JP2006508039A (ja) 2006-03-09
CA2844639A1 (en) 2004-01-08
ES2637011T3 (es) 2017-10-10
WO2004002421A2 (en) 2004-01-08
IL165973A0 (en) 2006-01-15
US20080038275A1 (en) 2008-02-14
JP2016145220A (ja) 2016-08-12
WO2004002500A1 (en) 2004-01-08
AU2008212004A1 (en) 2008-09-25
AU2003247813B2 (en) 2008-06-05
CA2490186A1 (en) 2004-01-08
JP2013139478A (ja) 2013-07-18
EP2314627B1 (en) 2017-07-26
US7258859B2 (en) 2007-08-21
US7575742B2 (en) 2009-08-18
AU2003247813A1 (en) 2004-01-19
HK1074769A1 (en) 2005-11-25
HK1249850A1 (en) 2018-11-16
EP1539200A2 (en) 2005-06-15
LU93315I2 (fr) 2017-01-26
US20190002575A1 (en) 2019-01-03
AU2003247813C1 (en) 2010-07-22
US8636997B2 (en) 2014-01-28
US20040109859A1 (en) 2004-06-10
JP5905534B2 (ja) 2016-04-20
SI1539200T1 (sl) 2014-09-30
US20130095069A1 (en) 2013-04-18
ES2474718T3 (es) 2014-07-09
EP3269377A1 (en) 2018-01-17
JP2014221813A (ja) 2014-11-27
HUS1600050I1 (hu) 2017-06-28
US20050249704A1 (en) 2005-11-10
US20170190779A1 (en) 2017-07-06
WO2004002421A3 (en) 2004-09-02
CA2490804A1 (en) 2004-01-08
AU2008212004B2 (en) 2010-10-21
US20130017152A1 (en) 2013-01-17
PT1539200E (pt) 2014-08-25
US20090175823A1 (en) 2009-07-09
US20180237532A1 (en) 2018-08-23
AU2002368055A1 (en) 2004-01-19
US8454965B2 (en) 2013-06-04
DK2314627T3 (en) 2017-10-23
CY1119389T1 (el) 2018-02-14
EP2314627A2 (en) 2011-04-27
JP2011157378A (ja) 2011-08-18
US20150010477A1 (en) 2015-01-08
HUE036677T2 (hu) 2018-07-30
IL241920A0 (en) 2015-11-30
PT2314627T (pt) 2017-08-29
CY2016043I1 (el) 2017-04-05
US20150337044A1 (en) 2015-11-26
JP2010132660A (ja) 2010-06-17
JP2013032372A (ja) 2013-02-14
EP1539200A4 (en) 2007-11-07
AU2002368055B2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
US8636997B2 (en) Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist
JP2010132660A5 (enExample)
CN105188751A (zh) 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法
JP2022548004A (ja) オマリズマブを使用した治療方法
HK1157192A (en) Method for the treatment of multiple sclerosis
HK1157192B (en) Method for the treatment of multiple sclerosis
HK1074769B (en) Method for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090406

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120106

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120308